Titan Could Have An Alien Biosphere – But It Might Be Dog-Sized
In disappointing news for alien hunters, the cycle of energy and nutrients in Titan's hypothetical biosphere may barely be enough to satisfy a single fermenting cell per liter of the moon's deep ocean, says evolutionary biologist Antonin Affholder from the University of Arizona.
Tantalizing Titan is unique in the Solar System. Compared to other icy moons, some of which may also harbor life in subsurface oceans, Titan has plentiful organic content, Affholder says.
Related:
Hydrocarbons on its surface liquify at a frigid -179 degrees Celsius (-290 degrees Fahrenheit), collecting in rivers and pools as large as our own Great Lakes.
Titan also hides a subsurface water ocean beneath its icy crust. In cross-section, the 5,150-kilometer (3,200-mile) wide Titan may resemble a planetary-scale jawbreaker candy, with five distinct layers, according to Cassini-Huygens data.
These layers hypothetically begin with a rocky core, then a layer of otherworldly 'ice-VI' – an alien ice that only exists at extremely high pressures. Above this sits the salty water ocean. The ocean is sealed by an outer layer of water-ice, which may be about 100 kilometers thick.
This outer water-ice layer forms Titan's bedrock, which is continually dusted by organic molecules that fall as raindrops from methane clouds, or settle as solid particles out of the hazy, yellowish atmosphere.
In the upper reaches of the atmosphere, molecules of nitrogen and methane are split apart by UV radiation from the Sun, and then recombine into a variety of heavy organic molecules rich in carbon and oxygen. As they gather on the surface they form tall, dark dunes that resemble mounds of coffee grounds as they fall back to the surface.
This bounty of organic molecules may seep into Titan's underground ocean through melt pools formed by meteorite impacts that crack and melt the ice crust. Organic molecules may also drift up into the watery ocean from Titan's rocky core.
In the new study, researchers used bioenergetic modeling to ascertain whether these organic molecules could offer the energy to sustain a community of microbes in Titan's ocean. These microbes could have evolved to produce energy by breaking down glycine, not unlike the class of bacterium Clostridia does here on Earth.
Here on Earth, a diverse array of life forms have made use of oxygen as way to conveniently rearrange energetic compounds for growth and energy.
Deprived of this powerful element, Titan's microbes could utilize a process of anaerobic respiration similar to one here on Earth known as fermentation.
Accordingly, the researchers say they chose this "simplest and most remarkable of all biological metabolic processes" because it does not require any speculations on wildly unknown alien metabolisms.
Fermentation on other ocean worlds could be plausible because it's a proven strategy on Earth; a ubiquitous and ancient process that now provides Earthlings with culinary favorites like sourdough, yogurt, and beer – yet also food spoilage if left unchecked.
Additionally, glycine and its precursors are very common throughout the Universe. These molecules are embedded in asteroids, comets, and the clouds of gas and dust that condense into stars and planets.
However, even though organic molecules like glycine have been enriching Titan's ocean on geologic timescales, only a piddling portion of this organic inventory may be suitable for microbial consumption.
This may mean that across Titan's vast ocean, the overall weight of life could measure "only a few kilograms at most – equivalent to the mass of a small dog," Affholder explains.
In other metrics, researchers add that the biosphere would average much "less than 1 cell per kg [2.205 lb] of water over the entire ocean." Or, the carbon content of a single, approximately 110-pound human.
With such a Lilliputian population scattered throughout an expansive environment, discovering a living cell would be akin to finding a needle in a haystack – a haystack approximately 800 million miles away.
This study was published in The Planetary Science Journal.
At 1.3 Billion Light-Years Wide, Quipu Is Officially The Biggest Thing in Our Universe
NASA Discovery Could Explain Why We've Never Found Life on Mars
Curiosity Cracked Open a Rock on Mars And Discovered a Huge Surprise
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
ART12.11, the Patented CBD:TMP Cocrystal, Demonstrates Potent Antidepressant-Like Activity and Cognitive Benefits Over Leading SSRI Data Being Presented at the 35th Annual International Cannabinoid Research Society Symposium SOLANA BEACH, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced the presentation of compelling new preclinical data on its Cannabidiol (CBD) and Tetramethylpyrazine (TMP) cocrystal drug candidate, ART12.11, at the 35th Annual International Cannabinoid Research Society (ICRS) Symposium, taking place July 6–10 in Bloomington, Indiana. The poster, titled 'ART12.11, A Novel Cannabidiol:Tetramethylpyrazine Cocrystal, Alleviates Stress-Induced Depressive Symptoms,' is being presented today by Matt Jones, a scientist working in the laboratory of Professor Steven Laviolette at the University of Western Ontario, Canada. The data highlight ART12.11's unique dual-action profile in improving depression-related behaviors in animals and reversing cognitive deficits associated with chronic stress. These are key differentiators that position ART12.11 as a potential next-generation treatment candidate in the multi-billion-dollar antidepressant market. Highlights: Robust Antidepressant-like Effects: A 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress. The data with ART12.11 demonstrated efficacy on par with sertraline (Zoloft), a leading selective serotonin reuptake inhibitor (SSRI). Restoration of Hedonic and Social Behaviors: Like sertraline, ART12.11 improved sucrose preference and social motivation, which are established behavioral markers of depressive-like states, to near-baseline levels. Superior Cognitive Restoration: Unlike sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory. Differentiated Therapeutic Profile: These findings underscore ART12.11's potential as a highly differentiated candidate for treating depression and anxiety, especially in patients where cognitive dysfunction occurs, which is a known limitation of existing SSRI therapies. 'Our latest behavioral studies suggest that the cocrystal holds strong potential as a novel antidepressant. In a stressed rodent model, ART12.11 significantly restored key depression-related behaviors to baseline levels. The ability to experience pleasure and social motivation with ART12.11 were comparable to the effects of the established antidepressant sertraline. Notably, ART12.11 also reversed stress-induced cognitive impairments, which is an area where sertraline was not as effective,' said Matt Jones, the lead researcher of this work at the University of Western Ontario. Prior preclinical research studies in animals with ART12.11 demonstrated greater behavioral and pharmacokinetic results compared to CBD or Epidiolex. These new findings observed in Dr. Laviolette's laboratory are from the first preclinical study that compared ART12.11 to a leading SSRI. 'Although strong antidepressant effects were noted with ART12.11 in prior studies, we are especially encouraged by these comparative findings,' said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. 'We believe ART12.11 has the potential to meet a critical need in the mental health landscape by delivering both mood-lifting and cognitive benefits. which could set ART12.11 apart from existing antidepressants.' About ART12.11ART12.11 is Artelo's wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Superior pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The US issued composition of matter patent for ART12.11 is enforceable until December 10, 2038 and has now been granted or validated in 19 additional countries. About Artelo BiosciencesArtelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and X: @ArteloBio. About the International Cannabinoid Research SocietyThe International Cannabinoid Research Society (ICRS) is the premier global scientific association with more than 650 international members from 40 countries, all active researchers in the field of endogenous, plant-derived, and synthetic cannabinoids and related bioactive lipids. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research. The ICRS Symposium is being held July 6-10, 2025 in Bloomington, IN. Interested parties may follow @ICRS_Society on X. Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's future investment policy of its excess capital, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,' 'project,' 'should,' 'would' and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Are some movie franchises like Jurassic World immune to bad reviews?
It looks like life has found a way for Jurassic World Rebirth to enjoy a pretty great opening weekend, despite an attack of middling reviews. Set five years after Colin Trevorrow's 2022 legacy-trilogy-capper Jurassic World: Dominion, director Gareth Edwards' Rebirth takes things back to basics. With the world's dinosaur population dying out, a team of experts must visit their last remaining hot spot to gather blood samples that could have revolutionary healthcare benefits. That's the elevator pitch. Big-name stars like Scarlett Johansson, Mahershala Ali and Jonathan Bailey fill in the gaps, with original Jurassic Park co-scribe David Koepp on script duty and - oh yeah - plenty of toothy prehistoric beasts. It's a combination that seems to have worked wonders. That stomping sound you can hear in the distance isn't an impending T-Rex attack. It's actually hoards of dino fans rushing to see Jurassic World Rebirth. Since its release last week, Edwards' sequel has so far bagged $318.3 million at the global box office — and that number is only expected to grow. When it comes to cinema ticket sales, it's a huge bite chomped during uncertain times. It's also a return on investment (the film reportedly cost Universal around $180 million) that sets Rebirth up nicely to become one of the biggest blockbuster releases of 2025. Its success seemingly flies in the face of all the mixed write-ups that have accompanied Rebirth's debut. A quick Google search throws up plenty of differing opinions on Edwards' sequel. From glowing critiques to those suggesting the whole franchise should finally be allowed to go extinct. As it turns out, none of them seemed to matter at all. By the looks of it, some franchises may be too big to be bothered by critical opinion. Like a mosquito on the back of a giant Brachiosaurus, they simply go unnoticed. While it should always be taken with a hearty pinch of salt, the perspective offered by movie aggregator site Rotten Tomatoes provides an insightful overview. Currently, Jurassic Park: Rebirth holds a 52% critic score, leaving it certified rotten in the eyes of many critics and their reviews. However, its audience rating tells a different story. Here, the film is a fresh success based on more than 5,000 audience reviews, many of whom seemingly love seeing people being eaten by big lizards. Of course, sites like this can be easily manipulated — but box office receipts can't lie. Even though critics have told us quite plainly that Jurassic World: Rebirth is the latest story in a franchise that's already on its last legs, movie fans don't seem to care. For many, someone else's critical opinion of a well-loved franchise will never matter. In the words of Jeff Bridges' stoner philosopher The Dude, "That's just like, your opinion, man" — and it is. When it comes to the Jurassic Park franchise, the bulk of Universal's target audience is in too deep to actually care what anyone else thinks. Many of them — likely millennials — no doubt grew up with Steven Spielberg's original and its 1997 sequel. The same crowd likely eagerly showed up for Joe Johnston's Jurassic Park III and later got a little misty-eyed during 2015's Jurassic World, which landed just in time for its original fans to pass on to the next generation. For this lot, no amount of reviews — positive, negative or otherwise — will be enough to dampen their interest in a return to Isla Nublar… or its increasingly extensive list of previously unknown sibling sites. And let's not underestimate the enduring appeal of dinosaurs. Kids just love dinosaurs. The Jurassic Park franchise is the only reliable source for seeing dinosaurs in the CGI flesh on the big screen, so families continue to turn up in droves from for a dose of supersized dino action. It's not just Jurassic World Rebirth reviews that fall into this category either. There are other outlier franchises where reviews suddenly become meaningless, and as you might expect, many have roots in pop culture nostalgia. Jon Favreau's live-action cookie-cutter remake of Disney's 1994 classic The Lion King remains a 52% critical dud but it banked over one billion in ticket sales. Likewise, Star Wars fans are so invested that even their most divisive entry — one littered with enough differing critical takes to fill a trash compactor — didn't stop fans from turning up in droves. Today, The Last Jedi remains the second most successful Star Wars entry ever made. So yeah, maybe the data does show that some movie franchises are just untouchable, regardless of whatever society's so-called tastemakers think about their overall quality. With that in mind, it's probably worth us all holding onto our butts - because surely this means more even Jurassic World stories will be heading our way soon.
Yahoo
2 hours ago
- Yahoo
First Lung Organoid with Organ-Specific Blood Vessels
Advanced lab-grown tissues help show how special lung cells develop, shedding light on rare ACDMPV disease and suggesting potential ways to repair damage from viral infections such as COVID-19 CINCINNATI, June 30, 2025 /PRNewswire/ -- A team of experts at Cincinnati Children's reports another powerful step forward in organoid medicine: success at making human lung tissue that can produce its own blood vessels. Their findings, published in the same month as a similar success involving liver organoids, reflect a new wave of advanced lab-grown tissues that can be used immediately in many research applications while moving ever closer to serving as living tissues that can directly repair damaged organs. Details were posted online June 30, 2025, in the journal Cell. "Prior to our study, the development of lung organoids with organotypic vasculature had not been achieved," says co-corresponding author Mingxia Gu, MD, PhD. "Notably, this method also could be applied to other organ systems such as intestine and colon." Gu, now at UCLA, was a member of the Center for Stem Cell and Organoid Medicine (CuSTOM) and Division of Pulmonary Biology at Cincinnati Children's while this research was conducted. Co-first and co-corresponding author Yifei Miao, PhD, (now at the Chinese Academy of Sciences, Beijing) also was with Cincinnati Children's for this work. Co-corresponding author Minzhe Guo, PhD, remains with Cincinnati Children's along with several co-authors involved in this study. Overcoming a major challenge Researchers have been working for years to grow organoids -- sometimes called "organs in a dish." Creating organoids involves converting mature human cells (such as blood or tissue cells) back into fetal-like stem cells that can be coaxed into growing a wide range of other tissue types. Unlike disconnected human cells kept alive in a dish, these are growing, developing mini-organs that form into seed-sized spheres that mimic the unique functions of full-sized organs. Intestines that absorb and secrete. Stomachs that produce digestive acids. Hearts that pulse. Brain tissues with firing nerve cells and so on. Cincinnati Children's has been a leader in organoid development since 2010 when experts here produced the world's first functional intestinal organoid grown from induced pluripotent stem cells (iPSCs). More recently, the challenge has been learning how to grow organoid tissues that can connect with the rest of the body to integrate nerve connections, blood vessels, bile ducts, immune systems and more. During pregnancy, these differing tissue types naturally find each other as the fetus matures and becomes more complex. Organoid developers seek to re-produce these steps in the laboratory, which eventually may allow people to receive custom-grown tissues that could patch damage or boost disrupted functions. Simpler forms of organoids have already begun transforming medical research, allowing many scientists to use living human tissue models to study disease while reducing current reliance on animal models to develop new medicines. But without the ability to make internal blood vessels, the tiny seeds lack the ability to grow into larger, more useful tissues. How the team solved the vascular riddle The new study thoroughly recounts the results of many experiments the team conducted to demonstrate success at inducing blood vessel formation. The work spanned four years and involved more than 20 people at Cincinnati Children's plus collaborations with experts at several other organizations. "The challenge in vascularizing endodermal organs, particularly the lung, stems from different signaling requirements for lung epithelial versus vascular differentiation," says Miao. "Our success in this endeavor is attributable to our unique differentiation method." In essence, the team grew iPSCs from multiple cell types then found the right moment to introduce them to each other. The resulting cell signals helped flip a developmental switch so that progenitor cells that could have become either blood vessels or the outer walls of the lung wound up becoming blood vessels. In achieving this vital step, the team: Produced lung organoids that include respiratory bronchial epithelial cells (RAS cells), a human cell type not previously reported in conventional lung organoid models. Pinned down the developmental moments when a rudimentary gut tube begins to send some cells to form the lungs while sending other cells to form the stomach and intestine. While the basic steps of this transformation have been studied in animals, it had not been possible to study this stage of development in humans without killing fetuses. Demonstrated that the rare disease ACDMPV occurs when cell signaling "crosstalk" gets disrupted during this early blood vessel formation stage. Within days of birth, infants born with Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) struggle to breathe because their lungs' air sacs (alveoli) and blood vessels are malformed. Nearly all infants with this condition die within the first month of life, according to the National Organization for Rare Disorders. Revealed key functional information about the cells involved in gas exchange inside the human lung. Their learnings help explain the damage within tiny blood capillaries that occurs in the lungs in response to injuries. These new clues offer fresh ideas for developing ways to protect and potentially restore affected lung tissues. What's Next? Cincinnati Children's has filed patent applications related to the methods developed here to produce organoids with blood vessel formation capabilities and the CuSTOM team is moving to further develop this technology. "We look forward to continuing to learn more about the fundamental biology involved in organ formation and applying those discoveries to improving outcomes across a wide range of difficult human diseases and conditions," says Aaron Zorn, PhD, co-director of CuSTOM and director of the Division of Developmental Biology. In addition to publishing these findings in Cell, co-authors plan to present their work at the Keystone conference in Kyoto, Japan (iPSCs: Progress, Opportunities, and Challenges) in January 2026. About the study Cincinnati Children's co-equal first authors were Miao, Nicole Pek, BS, and Cheng Tan, MD. Contributing co-authors from Cincinnati Children's were Cheng Jiang, MS, Zhiyun Yu, PhD, Kentaro Iwasawa, MD, PhD, Min Shi, MD, PhD, Daniel Kechele, PhD, Nambirajan Sundaram, PhD, Victor Pastrana-Gomez, MSTP student, Debora Sinner, PhD, Cheng-Lun Na, PhD, Keishi Kishimoto, PhD, Jason Tchieu, PhD, Jeffrey Whitsett, MD, Kyle McCracken, MD, PhD, Michael Helmrath, MD, James Wells, PhD, Takanori Takebe, MD, PhD, and Aaron Zorn, PhD. Contributing co-authors included experts from Harvard Medical School, Icahn School of Medicine at Mount Sinai, Sophia Children's Hospital (The Netherlands), Boston University This research also was supported by the Discover Together Biobank, the Bio-Imaging and Analysis Facility, and the Integrated Pathology Research Core at Cincinnati Children's and the University of Cincinnati Proteomics Laboratory. Funding sources for this work included: the National Institutes of Health (R01HL166283, DK128799-01, N01-75N92020C00005 and R01HL095993); an Endowed Scholar Award from the Cincinnati Children's Research Foundation; the American Heart Association (1013861 and 906513); the Falk Transformational Awards Program; and the Brigham Research Institute. Learn more about working with CuSTOM Learn how donors can support ongoing organoid research at Cincinnati Children's View original content to download multimedia: SOURCE Cincinnati Children's Hospital Medical Center Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data